Please login to the form below

Not currently logged in

Sun Pharma recalls antidepressant in US

Withdraws more than 40,000 bottles of venlafaxine hydrochloride
Sun Pharma

India-based Sun Pharmaceutical Industries is to recall more than 40,000 bottles of an antidepressant after the drug was discovered to have problems dissolving in the body.

US regulator the FDA announced the recall of venlafaxine hydrochloride last week, stating: “Stability results found the product did not meet the drug release dissolution specifications.”

Sun now has to withdraw 26,530 bottles of 30 pills of the depression treatment and 14,597 bottles containing 90 pills.

The FDA classed the recall as class II, meaning that this is a situation in which use of or exposure to a product may cause temporary or medically reversible adverse health consequences. However, the probability of serious adverse health consequences is remote compared to class I.

Venlafaxine hydrochloride is part of the serotonin-norepinephrine reuptake inhibitor (SNRI) class of medicines to treat people with major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder.

Sun Pharma's product is is a generic version of Pfizer/Wyeth's Effexor XR, which itself faced a recall earlier this year after one bottle was reported to contain a heart drug.

This is the latest in a series of setbacks for Sun Pharma in the US. During 2014 so far the company has faced a recall of chemotherapy drug gemcitabine due to sterility issues, while in January the company withdrew 2,528 bottles of its generic version of metformin.

The company has also come under criticism for its operations in India, with the FDA banning imports from a plant in Karkhadi and sending a warning letter detailing how employees deleted records of batch failures.

Article by
Thomas Meek

14th July 2014

From: Sales, Regulatory, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....